Affiliation:
1. 1Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology and
2. 2Robert-Bosch-Hospital, Stuttgart, Germany; and
3. 3DEFINIENS AG, Munich, Germany
Abstract
Abstract
Purpose: Breast cancer is composed of phenotypically diverse populations of cancer cells. The ability to form breast tumors has been shown by in vitro/in vivo studies to be restricted to epithelial tumor cells with CD44+/CD24−/low characteristics. Validation of these findings with respect to detection in clinical samples, prognosis, and clinical relevance is in demand.
Experimental Design: We investigated breast cancer tissues for the prevalence of CD44+/CD24−/low tumor cells and their prognostic value. The study included paraffin-embedded tissues of 136 patients with and without recurrences. In addition, a breast cancer progression array with normal, carcinoma in situ, and carcinoma tissues was analyzed. We applied double-staining immunohistochemistry for the detection of CD44+/CD24−/low cells. Evaluation was by microscopic pathologic inspection and automated image analysis.
Results: CD44+/CD24−/low cells ranged from 0% to 40% in normal breast and from 0% to 80% in breast tumor tissues. The prevalence of CD44+/CD24−/low tumor cells in 122 tumors was ≤10% in the majority (78%) of cases and >10% in the remainder. There was no significant correlation between CD44+/CD24−/low tumor cell prevalence and tumor progression. Although recurrences of tumors with high percentages of CD44+/CD24−/low tumor cells were mainly distant, preferably osseous metastasis, there was no correlation with the event-free and overall survival. There was no influence on the response to different treatment modalities.
Conclusions: Our findings suggest that the prevalence of CD44+/CD24−/low tumor cells in breast cancer may not be associated with clinical outcome and survival but may favor distant metastasis.
Publisher
American Association for Cancer Research (AACR)
Reference14 articles.
1. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105–11.
2. Smalley M, Ashworth A. Stem cells and breast cancer: A field in transit. Nat Rev Cancer 2003;3:832–44.
3. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730–7.
4. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994;367:645–8.
5. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003;63:5821–8.
Cited by
35 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献